- Home
- VRCA vs NTIP Comparison
VRCA vs NTIP Comparison
Compare VRCA & NTIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRCA
- NTIP
- Stock Information
- Founded
- VRCA 2013
- NTIP 1990
- Country
- VRCA United States
- NTIP United States
- Employees
- VRCA N/A
- NTIP N/A
- Industry
- VRCA Biotechnology: Pharmaceutical Preparations
- NTIP Multi-Sector Companies
- Sector
- VRCA Health Care
- NTIP Miscellaneous
- Exchange
- VRCA Nasdaq
- NTIP Nasdaq
- Market Cap
- VRCA 32.7M
- NTIP 32.0M
- IPO Year
- VRCA 2018
- NTIP 1998
- Fundamental
- Price
- VRCA $3.77
- NTIP $1.44
- Analyst Decision
- VRCA Hold
- NTIP
- Analyst Count
- VRCA 2
- NTIP 0
- Target Price
- VRCA N/A
- NTIP N/A
- AVG Volume (30 Days)
- VRCA 247.5K
- NTIP 8.9K
- Earning Date
- VRCA 11-06-2025
- NTIP 11-06-2025
- Dividend Yield
- VRCA N/A
- NTIP 6.67%
- EPS Growth
- VRCA N/A
- NTIP N/A
- EPS
- VRCA N/A
- NTIP N/A
- Revenue
- VRCA $14,704,000.00
- NTIP $150,000.00
- Revenue This Year
- VRCA $332.45
- NTIP N/A
- Revenue Next Year
- VRCA $12.85
- NTIP N/A
- P/E Ratio
- VRCA N/A
- NTIP N/A
- Revenue Growth
- VRCA 5.72
- NTIP N/A
- 52 Week Low
- VRCA $3.28
- NTIP $1.16
- 52 Week High
- VRCA $13.60
- NTIP $1.90
- Technical
- Relative Strength Index (RSI)
- VRCA 44.18
- NTIP 46.46
- Support Level
- VRCA $3.37
- NTIP $1.42
- Resistance Level
- VRCA $3.99
- NTIP $1.58
- Average True Range (ATR)
- VRCA 0.25
- NTIP 0.05
- MACD
- VRCA 0.03
- NTIP -0.00
- Stochastic Oscillator
- VRCA 45.12
- NTIP 37.50
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.